PROGRESSIVE MUSCULAR-DYSTROPHY AND MEDICI NAL RISK

Many therapeutic agents are necessary during the evolution of progress ive muscular dystrophy to cure intercurrent diseases. Some of them may impair muscular structure and induce rhabdomyolysis, toxic or inflamm atory myopathy. Other treatments may produce metabolic and functionnal alterations or impair cardiac and respiratory functions, yet endanged in progressive muscular dystrophy. They must be contra-indicated or u sed carefully during progressive muscular dystrophy.